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However, infliximab is very expensive to use as a second-line drug in refractory KD in developing countries. Therefore, one of our authors have previously used low-dose oral methotrexate as a treatment for patients with refractory KD. 2 In his study, methotrexate treatment resulted in rapid defervescence, improvement in clinical symptoms, normalizationm of acute-phase reactants, and no progression of coronary artery dilatation in severe KD patients resistant to additional IVIG and intravenous dexamethasone.
2 Methotrexate was also discontinued with no recurrence of fever in all patients. 2 Because methotrexate is cheap, easy to administer (oral, weekly), easily available and less toxic than infliximab, it could effectively be used before applying infliximab to KD patients refractory to additional IVIG or high-dose steroid therapy.
Also, we should think about the responsiveness to infliximab in patients with KD. Although not studied in KD, Martínez-Borra et al. reported that high serum TNF-α levels were associated with lack of response to infliximab in fistulizing Crohn's disease. 3 Marotte et al. also demonstrated that the level of circulating TNF-α bioactivity was higher in good responders than in poor responders, although the TNF-α protein levels were not associated with the response to infliximab. 4 In conclusion, because coronary artery aneurysm can develop within a relatively short time in young infants, low-dose oral methotrexate could be one of the useful drugs in refractory KD before considering infliximab. Further studies are also necessary to identify the factors predictive of the clinical response to infliximab in KD, and the relationship between the responsiveness to infliximab and the degree of increased serum TNF-α levels or circulating TNF-α bioactivity should be further elucidated in the future.
